Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) originally developed at the Institute of Molecular Genetics, Russian Academy of Sciences. It is a modified analogue of the endogenous adrenocorticotropic hormone (ACTH) fragment 4–10, extended with a C-terminal Pro-Gly-Pro sequence to increase resistance to enzymatic degradation. Published research has examined Semax in the context of BDNF and NGF neurotrophic factor expression, dopaminergic and serotonergic pathway modulation, and gene expression profiling in neuronal cultures. It is one of the most extensively studied nootropic peptides in Russian pharmacological literature, with over 80 published papers. Supplied as a >99% purity lyophilised powder.

This product is intended strictly for laboratory research use only. It is not approved for human or veterinary consumption or for use in diagnostic or therapeutic procedures.

• Purity: >99%
• Form: Lyophilised powder
• Intended use: Laboratory research only